JAKARTA (Yosefardi) – Pharmaceutical companies targets sales growth of 10% for 2015 though the rupiah further correction against the US dollar might affect their growth.
Pharmaceutical company PT Kalbe Farma Tbk (KLBF) targets its sales to grow by 10-15% to Rp20 trillion next year, from Rp1.7 trillion estimated for this year.
KLBF allocates capital expenditure (capex) of Rp1 trillion to Rp1.5 trillion for supporting revenue growth next year. It will use 80% of capex to fund its factory capacity expansion.
While PT Phapros Tbk, unit of Rajawali Nusantara Indonesia, targets its sales to grow by 16% to Rp675 billion in 2015 while net profit is expected to grow by 25% to Rp67 billion. It allocates capex of Rp151 billion for next year.
State pharmaceutical companies PT Kimia Farma Tbk (KAEF) and Indofarma Tbk (INAF) also targets sales to grow by 13% and 17% respectively in 2015. Kimia Farma ecpects to book sales of Rp4.8 trillion this year and Rp5.5 trillion next year.
Indofarma expects to book sales of Rp1.4 trillion this year and Rp1.7 trillion next year. It also targets to book net profit of Rp40 billion in 2015.